Results 241 to 250 of about 102,229 (258)

Phosphodiesterase Inhibitors

2014
openaire   +2 more sources

Lung cancer: New biological insights and recent therapeutic advances

Ca-A Cancer Journal for Clinicians, 2011
Suresh S Ramalingam, Fadlo R Khuri
exaly  

NTRK fusion-positive cancers and TRK inhibitor therapy

Nature Reviews Clinical Oncology, 2018
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon   +2 more
exaly  

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Reviews Cancer, 2019
Jonathan J Havel, Diego Chowell, Timothy A Chan   +2 more
exaly  

Appraising iniparib, the PARP inhibitor that never was—what must we learn?

Nature Reviews Clinical Oncology, 2013
Joaquin Mateo, Michael Ong, David S P Tan   +2 more
exaly  

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cell, 2020
Markus Hoffmann, Nadine Krüger, Tobias S Schiergens   +2 more
exaly  

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Nature Medicine, 2018
Yuting Sun, Jeffrey J Ackroyd, Stefan O Ciurea   +2 more
exaly  

Phosphodiesterase 4 Inhibitors

2001
Christopher H. Compton, Graham Sturton, Meretta J. Marks, Theodore J. Torphy   +3 more
openaire   +2 more sources

Phosphodiesterase Inhibitors

2007
openaire   +2 more sources

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

Nature Reviews Cancer, 2008
Ludger Hengst, Joyce M Slingerland
exaly